title: Bortezomib in multiple myeloma: systematic review and clinical considerations.
abstract: We conducted a systematic review to determine the appropriate use of bortezomib alone or in combination with other agents in patients with multiple myeloma (mm). We searched medline, embase, the Cochrane Library, conference proceedings, and the reference lists of included studies. We analyzed randomized controlled trials and systematic reviews if they involved adult mm patients treated with bortezomib and if they reported on survival, disease control, response, quality of life, or adverse effects. Twenty-six unique studies met the inclusion criteria. For patients with previously untreated mm and for candidates for transplantation, we found a statistically significant benefit in time to progression [hazard ratio (hr): 0.48, p < 0.001; and hr: 0.63, p = 0.006, respectively] and a better response with a bortezomib than with a non-bortezomib regimen (p < 0.001). Progression-free survival was longer with bortezomib and thalidomide than with thalidomide alone (p = 0.01). In non-candidates for transplantation, a significant benefit in overall survival was observed with a bortezomib regimen (hr compared with a non-bortezomib regimen: 0.61; p = 0.008), and in transplantation candidates receiving bortezomib, the response rate was improved after induction (p = 0.004) and after a first transplant (p = 0.016). In relapsed or refractory mm, overall survival (p = 0.03), time to progression (hr: 1.82; p = 0.000004), and progression-free survival (hr: 1.69; p = 0.000026) were significantly improved with bortezomib and pegylated liposomal doxorubicin (compared with bortezomib alone), and bortezomib monotherapy was better than dexamethasone alone (hr: 0.77; p = 0.027). Bortezomib combined with thalidomide and dexamethasone was better than either bortezomib monotherapy or thalidomide with dexamethasone (p < 0.001). In previously untreated or in relapsed or refractory mm patients, bortezomib-based therapy has improved disease control and, in some patients, overall survival.
authors.affiliation: Juravinski Cancer Centre, Hamilton, ON.
authors.forename: T C
authors.initials: TC
authors.lastname: Kouroukis
authors.affiliation: Program in Evidence-Based Care, Cancer Care Ontario, Hamilton, ON.
authors.forename: F G
authors.initials: FG
authors.lastname: Baldassarre
authors.affiliation: Program in Evidence-Based Care, Cancer Care Ontario, Hamilton, ON.
authors.forename: A E
authors.initials: AE
authors.lastname: Haynes
authors.affiliation: Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, ON.
authors.forename: K
authors.initials: K
authors.lastname: Imrie
authors.affiliation: Princess Margaret Hospital, Toronto, ON.
authors.forename: D E
authors.initials: DE
authors.lastname: Reece
authors.affiliation: Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, ON.
authors.forename: M C
authors.initials: MC
authors.lastname: Cheung
keywords: Bortezomib; multiple myeloma; proteasome inhibitors; systematic review
references.citation: Curr Oncol. 2006 Oct;13(5):160-72
references.pmid: 22792013
references.citation: Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67
references.pmid: 20306195
references.citation: J Clin Oncol. 2012 Aug 20;30(24):2946-55
references.pmid: 22802322
references.citation: Eur J Haematol. 2010 May;84(5):379-90
references.pmid: 20345446
references.citation: Blood. 2012 Sep 27;120(13):2581-8
references.pmid: 22889759
references.citation: Cancer. 2012 May 1;118(9):2507-15
references.pmid: 21887685
references.citation: Ann Hematol. 2010 Nov;89(11):1133-40
references.pmid: 20532504
references.citation: J Clin Epidemiol. 2009 Oct;62(10):1013-20
references.pmid: 19230606
references.citation: Br J Haematol. 2008 Nov;143(4):511-9
references.pmid: 18986387
references.citation: Blood. 2012 Jul 5;120(1):9-19
references.pmid: 22498745
references.citation: Am J Hematol. 2011 Jan;86(1):18-24
references.pmid: 21120867
references.citation: Eur J Haematol. 2011 May;86(5):372-84
references.pmid: 21366694
references.citation: J Clin Oncol. 2010 May 1;28(13):2259-66
references.pmid: 20368561
references.citation: Clin Cancer Res. 2010 Oct 15;16(20):5079-86
references.pmid: 20739431
references.citation: Expert Opin Investig Drugs. 2009 Jul;18(7):957-71
references.pmid: 19505187
references.citation: Lancet Oncol. 2010 Oct;11(10):934-41
references.pmid: 20739218
references.citation: Leukemia. 2008 Apr;22(4):842-9
references.pmid: 18200040
references.citation: Hematol Oncol. 2012 Jun;30(2):57-61
references.pmid: 21809367
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2475-82
references.pmid: 22585692
references.citation: Pharmacogenet Genomics. 2011 Mar;21(3):121-9
references.pmid: 21228734
references.citation: Blood. 2011 Nov 24;118(22):5752-8; quiz 5982
references.pmid: 21849487
references.citation: Acta Haematol. 2011;126(3):163-8
references.pmid: 21778706
references.citation: Blood. 2007 Nov 15;110(10):3557-60
references.pmid: 17690257
references.citation: Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8
references.pmid: 14675309
references.citation: Blood. 2010 Dec 2;116(23):4745-53
references.pmid: 20807892
references.citation: Leuk Lymphoma. 2011 Mar;52(3):394-9
references.pmid: 21323520
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4784-90
references.pmid: 18711175
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6086-93
references.pmid: 19858394
references.citation: Blood. 2012 Jan 26;119(4):940-8
references.pmid: 22160383
references.citation: J Natl Compr Canc Netw. 2009 Oct;7(9):908-42
references.pmid: 19878637
references.citation: Lancet. 2010 Dec 18;376(9758):2075-85
references.pmid: 21146205
references.citation: N Engl J Med. 2008 Aug 28;359(9):906-17
references.pmid: 18753647
references.citation: Lancet Oncol. 2011 May;12(5):431-40
references.pmid: 21507715
references.citation: Br J Haematol. 2011 Jul;154(1):32-75
references.pmid: 21569004
references.citation: Cancer Treat Rev. 2008 Aug;34(5):442-52
references.pmid: 18381234
references.citation: Eur J Haematol. 2011 Jan;86(1):23-31
references.pmid: 20874823
references.citation: Leukemia. 2010 Jun;24(6):1233-5
references.pmid: 20428201
references.citation: Ann Hematol. 2012 Jun;91(6):875-88
references.pmid: 22476884
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5101-9
references.pmid: 20940200
references.citation: Br J Haematol. 2009 Mar;144(6):895-903
references.pmid: 19170677
references.citation: Br J Haematol. 2008 Oct;143(1):46-53
references.pmid: 18673366
references.citation: Br J Haematol. 2007 Jun;137(5):429-35
references.pmid: 17451408
references.citation: Leuk Lymphoma. 2010 Aug;51(8):1424-43
references.pmid: 20509769
references.citation: Leukemia. 2009 Oct;23(10):1716-30
references.pmid: 19494840
references.citation: BMC Med Res Methodol. 2007 Feb 15;7:10
references.pmid: 17302989
references.citation: Lancet Oncol. 2011 Sep;12(9):837-8
references.pmid: 21984992
references.citation: Blood. 2011 Mar 17;117(11):3041-4
references.pmid: 21098740
references.citation: Br J Haematol. 2009 Nov;147(4):531-4
references.pmid: 19725827
references.citation: Eur J Haematol. 2012 Jun;88(6):485-96
references.pmid: 22404182
references.citation: Health Technol Assess. 2011 Dec;15(41):1-204
references.pmid: 22146234
references.citation: Blood. 2010 Nov 11;116(19):3743-50
references.pmid: 20628153
references.citation: J Clin Oncol. 2010 Oct 20;28(30):4621-9
references.pmid: 20823406
references.citation: Cancer. 2008 Apr 1;112(7):1529-37
references.pmid: 18300257
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727
references.citation: Blood. 2012 May 10;119(19):4375-82
references.pmid: 22422823